Additional file 1 of Impact of individual microvascular disease on the risks of macrovascular complications in type 2 diabetes: a nationwide population-based cohort study

Supplementary Material

Table_1_The Risk of Nephropathy, Retinopathy, and Leg Amputation in Patients With Diabetes and Hypertension: A Nationwide, Population-Based Retrospective Cohort Study.docx

PurposeTo compare the risks of chronic kidney disease (CKD), end-stage renal disease (ESRD), sight-threatening retinopathy, and leg amputation between patients with diabetes or hypertension.MethodsFrom January 1, 2000, to December 31, 2015, we identified 28943 matched pairs of patients with diabetes with and without subsequent hypertension, 89102 pairs of patients with hypertension with and without subsequent diabetes, and 145294 pairs of patients with coexisting diabetes and hypertension with a previous history of diabetes or hypertension from Taiwan’s National Health Insurance Research Database. Cox proportional-hazard models were used for calculating the risks of CKD, sight-threatening retinopathy, and leg amputation.ResultsThe mean follow-up time of this study in different cohorts was between 3.59 and 4.28 years. In diabetes patients with vs. without subsequent hypertension, hypertension patients with vs. without subsequent diabetes, and comorbid diabetes and hypertension patients with previous diabetes vs. with previous hypertension, the adjusted HRs (95% CIs) for CKD were 2.77 (2.61-2.94), 1.73 (1.68-1.77), and 1.04 (1.02-1.07); for ESRD were 42.38 (22.62-79.4), 2.76 (2.43-3.13), and 0.72 (0.66-0.79); for sight-threatening retinopathy were 2.07 (1.85-2.3), 3.41 (3.14-3.71), and for leg amputation were 1.51 (1.43-1.58); and 4.74 (3.02-7.43), 6.27(4.72-8.31), and 1.19(1.03-1.38).ConclusionsThis study demonstrated that both diabetes and hypertension are risk factors for the development of CKD, retinopathy, and amputation. Tracing subsequent diabetes for patients with hypertension, and hypertension for patients with diabetes are important in clinical settings.</p

The cumulative incidence curves of ischemic stroke estimated by cause-specific Cox proportional hazard regression model.

The cumulative incidence curves of ischemic stroke estimated by cause-specific Cox proportional hazard regression model.</p

Risk stratification for ischemic stroke in non-blepharitis and blepharitis cohorts.

Risk stratification for ischemic stroke in non-blepharitis and blepharitis cohorts.</p

Comparison of non-blepharitis and blepharitis cohorts.

Comparison of non-blepharitis and blepharitis cohorts.</p

Study flow chart.

IntroductionTo investigate the association of blepharitis and ischemic stroke.MethodsThis nationwide retrospective cohort study used population-based data in Taiwan. Individuals aged 20 and above with diagnosis of blepharitis was included based on electrical medical records. After exclusion of ineligible cases, 424,161 patients were identified between 2008 and 2018. The blepharitis and non-blepharitis cohorts were matched based on sex, age, and comorbidities. Multivariable-adjusted Cox proportional hazards model was adopted to calculate the hazard ratio and 95% confidence interval (CI) between blepharitis and non-blepharitis cohorts. The incidence of ischemic stroke was estimated by Kaplan–Meier analysis.Results424,161 pairs of blepharitis cohort and non-blepharitis cohort were 1:1 propensity score matched for statistical analysis. Patients with blepharitis had significantly increased risk of ischemic stroke compared with the individuals without blepharitis (adjusted hazard ratio 1.32, 95% CI 1.29–1.34, P P for interaction P P ConclusionsPatients with blepharitis had an elevated risk of developing ischemic stroke. Early treatment and active surveillance are suggested for patients with chronic blepharitis. Further research is required to determine the casual relationship between blepharitis and ischemic stroke, as well as the underlying mechanism.</div

The risks of ischemic stroke in the blepharitis cohort relative to the non-blepharitis cohort in terms of different follow-up time.

The risks of ischemic stroke in the blepharitis cohort relative to the non-blepharitis cohort in terms of different follow-up time.</p

Risk factors of ischemic stroke.

IntroductionTo investigate the association of blepharitis and ischemic stroke.MethodsThis nationwide retrospective cohort study used population-based data in Taiwan. Individuals aged 20 and above with diagnosis of blepharitis was included based on electrical medical records. After exclusion of ineligible cases, 424,161 patients were identified between 2008 and 2018. The blepharitis and non-blepharitis cohorts were matched based on sex, age, and comorbidities. Multivariable-adjusted Cox proportional hazards model was adopted to calculate the hazard ratio and 95% confidence interval (CI) between blepharitis and non-blepharitis cohorts. The incidence of ischemic stroke was estimated by Kaplan–Meier analysis.Results424,161 pairs of blepharitis cohort and non-blepharitis cohort were 1:1 propensity score matched for statistical analysis. Patients with blepharitis had significantly increased risk of ischemic stroke compared with the individuals without blepharitis (adjusted hazard ratio 1.32, 95% CI 1.29–1.34, P P for interaction P P ConclusionsPatients with blepharitis had an elevated risk of developing ischemic stroke. Early treatment and active surveillance are suggested for patients with chronic blepharitis. Further research is required to determine the casual relationship between blepharitis and ischemic stroke, as well as the underlying mechanism.</div

Additional file 1 of Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes

Additional file 1: Table S1. Diseases and related ICD-9-CM, ICD-10-CM codes. Table S2. The risk of all-cause death for T2D patients with and without GLP-1 RA stratified by variables. Table S3. The risk of cardiovascular death for T2D patients with and without GLP-1 RA stratified by variables. Table S4. The risk of cardiovascular events for T2D patients with and without GLP-1 RA stratified by variables. Table S5. The risk of liver-related death for T2D patients with and without GLP-1 RA stratified by variables. Fig. S1. Flowchart of patient selection in this study. Fig. S2. The cumulative incidences of major adverse cardiovascular events (MACE, a), cardiovascular death (b), between GLP-1 RA users and nonusers in persons with T2D

sj-docx-1-wso-10.1177_17474930221125556 – Supplemental material for Immune thrombocytopenia and risk of stroke: Evidence from a nationwide population-based cohort study

Supplemental material, sj-docx-1-wso-10.1177_17474930221125556 for Immune thrombocytopenia and risk of stroke: Evidence from a nationwide population-based cohort study by Hsin-Yu Chen, Wei-Kai Lee, Renin Chang, Yao-Min Hung, Chung Y Hsu, Ying-Hsiu Shih and Jin-Shuen Chen in International Journal of Stroke</p